The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assess feasibility of methylphenidate
Timeframe: Feasibility is measured during the initial recruitment process for each participant.
Assess acceptability of methylphenidate
Timeframe: Acceptability ratings are captured at baseline and after 4 weeks of treatment with methylphenidate.
Assess adherence to methylphenidate
Timeframe: Adherence is measured on a weekly basis through 4 weeks of treatment